Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors

Next Previous
Trial Profile

QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Avelumab (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Nogapendekin alfa inbakicept (Primary) ; PD-L1-t-haNK (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Cervical cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms QUILT-3.055
  • Sponsors Altor BioScience Corporation; ImmunityBio

Most Recent Events

  • 29 Jul 2026 According to an ImmunityBio media release, The Emirates Drug Establishment (EDE) of the United Arab Emirates (UAE) granted Marketing Authorization to ANKTIVA 1.2 mg/0.6 mL (solution for subcutaneous injection) in combination with immune checkpoint inhibitors for metastatic non-small cell lung cancer (NSCLC). The approval is supported by results from this study.
  • 17 Feb 2026 According to an ImmunityBio media release, based on the data from this basket trial- the scientific rationale for expanding ANKTIVA into additional tumor types in the CPI relapsed population has been discussed between ImmunityBio and SFDA.
  • 14 Jan 2026 According to an ImmunityBio media release, the Saudi Food and Drug Authority (SFDA) has granted accelerated approval of ANKTIVA (nogapendekin alfa inbakicept) for use in combination with immune checkpoint inhibitors for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose disease has progressed following standard-of-care therapy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top